Mitchell E. Gross

4.5k total citations
122 papers, 3.5k citations indexed

About

Mitchell E. Gross is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Mitchell E. Gross has authored 122 papers receiving a total of 3.5k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Pulmonary and Respiratory Medicine, 41 papers in Oncology and 27 papers in Molecular Biology. Recurrent topics in Mitchell E. Gross's work include Prostate Cancer Treatment and Research (57 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Mitchell E. Gross is often cited by papers focused on Prostate Cancer Treatment and Research (57 papers), Prostate Cancer Diagnosis and Treatment (13 papers) and Cancer Genomics and Diagnostics (12 papers). Mitchell E. Gross collaborates with scholars based in United States, Canada and France. Mitchell E. Gross's co-authors include David B. Agus, Ke Shuai, Tanya B. Dorff, George Wilding, Inderbir S. Gill, Osamu Ukimura, Andre Luis Abreu, Johanna ten Hoeve, Bin Liu and Chun‐Peng Liao and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and ACS Nano.

In The Last Decade

Mitchell E. Gross

119 papers receiving 3.4k citations

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Mitchell E. Gross 1.5k 1.2k 1.1k 667 423 122 3.5k
Aurelius Omlin 1.9k 1.3× 1.3k 1.1× 816 0.8× 985 1.5× 693 1.6× 115 3.6k
Kadri Altundağ 915 0.6× 2.5k 2.1× 717 0.7× 748 1.1× 361 0.9× 251 3.9k
Ondřej Topolčan 1.0k 0.7× 1.6k 1.3× 1.3k 1.2× 1.1k 1.6× 278 0.7× 254 4.2k
Takahiro Kimura 1.7k 1.1× 790 0.7× 1.3k 1.3× 811 1.2× 337 0.8× 325 4.0k
Paul Cozzi 911 0.6× 1.0k 0.9× 1.3k 1.2× 603 0.9× 281 0.7× 67 2.9k
María D. Lozano 1.8k 1.2× 1.1k 0.9× 1.0k 1.0× 717 1.1× 365 0.9× 151 3.7k
Wei Wei 1.5k 1.0× 1.8k 1.5× 902 0.9× 900 1.3× 1.1k 2.7× 243 5.2k
Takefumi Satoh 1.6k 1.1× 665 0.6× 878 0.8× 441 0.7× 445 1.1× 157 3.6k
Paul M. Clément 1.3k 0.9× 1.5k 1.3× 1.4k 1.3× 682 1.0× 408 1.0× 136 4.1k
Moshe Inbar 975 0.7× 1.7k 1.5× 669 0.6× 456 0.7× 253 0.6× 171 3.7k

Countries citing papers authored by Mitchell E. Gross

Since Specialization
Citations

This map shows the geographic impact of Mitchell E. Gross's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mitchell E. Gross with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mitchell E. Gross more than expected).

Fields of papers citing papers by Mitchell E. Gross

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mitchell E. Gross. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mitchell E. Gross. The network helps show where Mitchell E. Gross may publish in the future.

Co-authorship network of co-authors of Mitchell E. Gross

This figure shows the co-authorship network connecting the top 25 collaborators of Mitchell E. Gross. A scholar is included among the top collaborators of Mitchell E. Gross based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mitchell E. Gross. Mitchell E. Gross is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Walsh, David, Sumana Srivatsa, Renee D. George, et al.. (2023). Individualized treatment estimates to inform on personalized cancer care decisions for treatment selection and treatment management.. Journal of Clinical Oncology. 41(16_suppl). e13571–e13571. 1 indexed citations
2.
Liao, Chun‐Peng, et al.. (2023). Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration. Bioorganic & Medicinal Chemistry. 92. 117425–117425. 7 indexed citations
3.
Zhang, Ailin, et al.. (2021). In Vivo Non-Thermal, Selective Cancer Treatment With High-Frequency Medium-Intensity Focused Ultrasound. IEEE Access. 9. 122051–122066. 4 indexed citations
4.
Gross, Mitchell E., David B. Agus, Tanya B. Dorff, et al.. (2020). Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer. Prostate Cancer and Prostatic Diseases. 24(1). 61–68. 42 indexed citations
5.
Zhang, Ailin, Chun‐Peng Liao, Christopher Poon, et al.. (2020). CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation. Journal of Controlled Release. 329. 614–623. 33 indexed citations
6.
Gaur, Shikha, Mitchell E. Gross, Chun‐Peng Liao, Bin Qian, & Jean C. Shih. (2019). Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells. The Prostate. 79(6). 667–677. 47 indexed citations
7.
Matasci, Naim, et al.. (2019). Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA). BMC Research Notes. 12(1). 275–275. 21 indexed citations
8.
Tiemann, Katrin, Carolina Garri, Sang Bok Lee, et al.. (2018). Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis. Oncogene. 38(16). 3003–3018. 28 indexed citations
9.
Belic, Jelena, Ricarda Graf, Thomas Bauernhofer, et al.. (2018). Genomic alterations in plasma DNA from patients with metastasized prostate cancer receiving abiraterone or enzalutamide. International Journal of Cancer. 143(5). 1236–1248. 40 indexed citations
10.
Dorff, Tanya B., E. Todd Schroeder, George J. Salem, et al.. (2017). A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy. BMJ Open. 7(7). e016910–e016910. 13 indexed citations
11.
Dreicer, Robert, David B. MacLean, Ajit Suri, et al.. (2014). Phase I/II Trial of Orteronel (TAK-700)—an Investigational 17,20-Lyase Inhibitor—in Patients with Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 20(5). 1335–1344. 34 indexed citations
12.
Kani, Kian, Vítor M. Faça, Lindsey D. Hughes, et al.. (2012). Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition. Molecular Cancer Therapeutics. 11(5). 1071–1081. 6 indexed citations
13.
Lazar, Daniel C., Edward H. Cho, Madelyn Luttgen, et al.. (2012). Cytometric comparisons between circulating tumor cells from prostate cancer patients and the prostate-tumor-derived LNCaP cell line. Physical Biology. 9(1). 16002–16002. 53 indexed citations
14.
Jadvar, Hossein, Bhushan Desai, Lingyun Ji, et al.. (2012). Prospective Evaluation of 18F-NaF and 18F-FDG PET/CT in Detection of Occult Metastatic Disease in Biochemical Recurrence of Prostate Cancer. Clinical Nuclear Medicine. 37(7). 637–643. 100 indexed citations
15.
Wang, Lingtao, et al.. (2011). CELL LYSIS BY LOW POWER FOCUSED ACOUSTIC TRANSDUCER AND INVESTIGATION OF ACOUSTIC INTENSITY THRESHOLD FOR CYTOLYSIS OF VARIOUS CELL LINES. 434–436.
16.
Gross, Mitchell E., Lawrence Leichman, Elizabeth Lowe, Alan Swaisland, & David B. Agus. (2011). Safety and pharmacokinetics of high-dose gefitinib in patients with solid tumors: results of a phase I study. Cancer Chemotherapy and Pharmacology. 69(1). 273–280. 11 indexed citations
17.
Meyerowitz, Beth E., et al.. (2008). Predictors of affect following treatment decision‐making for prostate cancer: conversations, cognitive processing, and coping. Psycho-Oncology. 18(5). 508–514. 39 indexed citations
18.
Rosenberg, Jonathan E., Vivian Weinberg, William K. Kelly, et al.. (2007). Activity of second‐line chemotherapy in docetaxel‐refractory hormone‐refractory prostate cancer patients. Cancer. 110(3). 556–563. 138 indexed citations
19.
Gross, Mitchell E., et al.. (2004). Update on HER-kinase-directed therapy in prostate cancer.. PubMed. 2(1). 53–6, 64. 13 indexed citations
20.
Small, E. B. & Mitchell E. Gross. (1985). Preliminary observations of protistan organisms, especially ciliates, from the 21°N hydrothermal vent site. 401–410. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aurelius Omlin Breakdown of academic impact, for papers by Kadri Altundağ Breakdown of academic impact, for papers by Ondřej Topolčan Breakdown of academic impact, for papers by Takahiro Kimura Breakdown of academic impact, for papers by Paul Cozzi Breakdown of academic impact, for papers by María D. Lozano Breakdown of academic impact, for papers by Wei Wei Breakdown of academic impact, for papers by Takefumi Satoh Breakdown of academic impact, for papers by Paul M. Clément Breakdown of academic impact, for papers by Moshe Inbar
Rankless by CCL
2026